This case illustrates HLH as an uncommon but serious immune-mediated toxicity of BRAF/MEK inhibitors, and co-administration of ruxolitinib as a potentially safe and effective therapy in managing HLH-like hyperinflammatory syndrome triggered by BRAF/MEK inhibitors. The gene discussed is BRAF; the disease is hemophagocytic syndrome.